OEM/ODM Manufacturer Glioblastoma Multiforme - Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2 API High Quality – Ruifu

Supply Vonoprazan Fumarate and Related Intermediate 5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde CAS 881674-56-2 Pyridine-3-Sulfonyl Chloride CAS 16133-25-8 Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2

Chemical Name	Vonoprazan Fumarate
Synonyms	TAK-438
CAS Number	1260141-27-2; 881681-01-2
CAT Number	RF-API99
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C21H20FN3O6S
Molecular Weight	461.463
Brand	Ruifu Chemical

Item	Specifications
Appearance	White or Almost-White Crystalline Powder
Identification 1 H-NMR	Consistent with the Standard
Identification IR	The IR Absorption spectrum of the sample concordant with reference standard
Identification HPLC	The retention time of the sample concordant with reference standard
Related Substances
Impurity A	≤0.20%
Impurity B	≤0.15%
Impurity C	≤0.15%
Any Other Impurity	≤0.10%
Total Impurities	≤1.0%
Residual Solvents
Methanol	≤0.30%
Ethanol	≤0.50%
Ethyl Acetate	≤0.50%
Assay / Analysis Method	98.0%~102.0% (By HPLC)
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture. Vonoprazan Fumurate (TAK-438) (CAS: 1260141-27-2; 881681-01-2), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate (Takecab), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014. Vonoprazan Fumarate is mainly used for the treatment of helicobacter pylori infection, gastroesophageal reflux, peptic ulcer, duodenal ulcer, esophagitis, gastric ulcer and other gastric acid related diseases. The product has a strong, lasting inhibition of gastric acid secretion. At the treatment dose, Vonoprazan Fumarate has little effect on other enzymes and little effect on physiological functions of the body. It is safe and more tolerable.